Market closed

UroGen Pharma/$URGN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Ticker

$URGN
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Princeton, United States

Employees

217
Website
www.urogen.com

UroGen Pharma Metrics

BasicAdvanced
$430M
-
-$3.08
1.13
-

$430M

1.13

$20.70

$9.80

418K

9

8.307

477.84

481.074

-6.85%

-21.12%

1,400.39%

4.262

16.83

16.83

-3.952

15.64%

-25.05%

30.91%

-15.26%

What the Analysts think about UroGen Pharma

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.

UroGen Pharma Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

UroGen Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

UroGen Pharma News

AllArticlesVideos
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Business Wire·1 month ago
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

Business Wire·1 month ago
UroGen Pharma: Choice Based On Near Term High Value PDUFA

UroGen Pharma: Choice Based On Near Term High Value PDUFA

Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $URGN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for UroGen Pharma stock?

UroGen Pharma (URGN) has a market cap of $430M as of January 15, 2025.

What is the P/E ratio for UroGen Pharma stock?

The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of January 15, 2025.

Does UroGen Pharma stock pay dividends?

No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next UroGen Pharma dividend payment date?

UroGen Pharma (URGN) stock does not pay dividends to its shareholders.

What is the beta indicator for UroGen Pharma?

UroGen Pharma (URGN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.